Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis, a company into the development, manufacture and sale of generic pharmaceuticals, has received marketing approval from FDA for Bupropion HCl extended-release (SR) tablets of strengths 100mg and 200mg.
Subscribe to our email newsletter
Bupropion HCl SR tablets, used in the treatment of major depressive disorder, are the generic equivalent of GlaxoSmithKline’s Wellbutrin SR and are now available from Actavis in the 100mg, 150mg, and 200mg strengths.
Bupropion HCl SR primarily acts as a dopamine reuptake inhibitor. It also acts as a norepinephrine, as well as a3ß4-nicotinic receptor antagonist. Bupropion belongs to the chemical class of aminoketones and is similar in structure to stimulants cathinone and diethylpropion, and to phenethylamines in general.
Actavis has received approval of Bupropion HCl SR 150mg in March, 2008.
Michael Perfetto, vice president of the sales and marketing at Actavis in US, said: “The approval of Bupropion SR 100mg and 200mg allows Actavis to provide the full range of strengths available on both Bupropion SR and XL products.”